2022
DOI: 10.1016/j.bcp.2022.114991
|View full text |Cite
|
Sign up to set email alerts
|

Ruthenium(II) carbon monoxide releasing molecules: Structural perspective, antimicrobial and anti-inflammatory properties

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
11
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 17 publications
(12 citation statements)
references
References 155 publications
0
11
0
Order By: Relevance
“…In previous reports, the inhibition of the respiratory chain was implied as a target for a ruthenium-based CORM (of note, it has been questioned whether the antibacterial effect of Ru-CORMs is indeed due to CO-release). 52,53 To interrogate whether MnG9MeBeIm affects the respiratory chain we quantied the respiratory activity by monitoring resazurin reduction. 54 A dosedependent decrease in respiratory chain activity was observed (Fig.…”
Section: Effect Of Mng9mebeim On the Bacterial Membranementioning
confidence: 99%
“…In previous reports, the inhibition of the respiratory chain was implied as a target for a ruthenium-based CORM (of note, it has been questioned whether the antibacterial effect of Ru-CORMs is indeed due to CO-release). 52,53 To interrogate whether MnG9MeBeIm affects the respiratory chain we quantied the respiratory activity by monitoring resazurin reduction. 54 A dosedependent decrease in respiratory chain activity was observed (Fig.…”
Section: Effect Of Mng9mebeim On the Bacterial Membranementioning
confidence: 99%
“…Since reaching a plateau in the case of B took a longer time, 45 min, this complex is a slow CO releaser, which makes it an excellent candidate for pharmacological applications. 40 The photoactivatable CO release process from A and B after exposure to the 468 nm LED was investigated using the myoglobin assay. 33,34 Despite a few drawbacks, such as CO release being dependent on the amount of dithionite present, 33 interferences from highly coloured CORMs, and the myoglobin In general, the half-life of the CO release process is a crucial parameter for prospective therapeutic applications.…”
Section: Dalton Transactions Communicationmentioning
confidence: 99%
“…Since reaching a plateau in the case of B took a longer time, 45 min, this complex is a slow CO releaser, which makes it an excellent candidate for pharmacological applications. 40…”
mentioning
confidence: 99%
“…Although haemoglobin may even effectively bind oxygen in this situation, the amount of O 2 delivered to tissues is drastically decreased. 1 When the level of COHb increases, people may have headaches, followed by nausea, dizziness, and altered eyesight, before dying at COHb levels of 50% or higher. Alternatively, it has been well known that the two haem-oxygenase isoforms cooperate to increase the body's CO levels by progressively breaking down haem as part of the catabolism of haemoglobin and other haem-containing proteins.…”
mentioning
confidence: 99%
“…On the other hand, most of the Ru( ii ) photoCORMs that have been published are either inert or emit CO when exposed to UV light, in contrast to their Mn( i ) equivalents. 1 The investigation into CORMs as CO prodrugs only included di- and tricarbonyl Ru( ii )-based CORMs. In this communication, we report the potential of two photoactivatable cis -Mn(CO) I 2 ( 1 ) and Ru(CO) II based CORMs, functionalized with diphenyl pyridyl phosphine (PPh 2 Py), to act as CO prodrugs upon exposure to a light source in the range of 365–468 nm (Scheme 1).…”
mentioning
confidence: 99%